Viridian Therapeutics, Inc. (VRDN) Market Cap & Valuation Ratios
Viridian Therapeutics, Inc. (VRDN) has a market cap of $2.5B and a price-to-sales ratio of 35.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VRDNViridian Therapeutics, Inc.Follow VRDN — free
—
Price chart with a free account
- Market cap
- 2.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| VRDN | 2.5 | — | 26.8 | — | -13.2% | — | — | -48% |
| IRON | 2.9 | — | — | — | -6.9% | — | — | -48% |
| VKTX | 2.8 | — | — | — | -14.7% | — | — | -107% |
| NRIX | 2.8 | 10.0 | 2.9 | 6.9 | 13.4% | +739% | 41% | 102% |
| BEAM | 2.5 | — | 9.2 | — | — | +159% | -242% | -43% |
| ADMA | 2.4 | 15.3 | 4.8 | 10.6 | 4.9% | +8% | 44% | 37% |
| RCUS | 2.4 | — | 15.0 | — | — | -55% | -415% | -120% |
| MBX | 2.3 | — | — | — | -3.6% | — | — | -44% |
| SLS | 2.3 | — | — | — | — | — | — | — |
| CLDX | 2.3 | — | — | — | -10.5% | -97% | — | -50% |
| FTRE | 2.2 | — | 1.2 | 46.4 | 8.7% | -2% | -0.4% | -0.7% |
| Median of these 10 | 12.6 | 4.8 | 10.6 | -3.6% | +3% | -0.4% | -44% |
; EV/Sales 26.8 vs. 4.8.
Growth vs. price
each dot a company · hover or tap for valuesViridian Therapeutics, Inc. — questions
- What is Viridian Therapeutics, Inc.'s market cap?
- $2.5B.
- What is Viridian Therapeutics, Inc.'s price-to-sales ratio?
- 35.6.
Every figure on this page comes from Viridian Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.